Enzymatica AB (ENZY) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Jun 25

NET SALES(Q) At SEK 8.28 MM has Fallen at -31.6%
OPERATING CASH FLOW(Y) Lowest at SEK -64.06 MM
RAW MATERIAL COST(Y) Grown by 12.17% (YoY)

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 466 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.23

Return on Equity

-39.90%

Price to Book

3.43

Revenue and Profits:

Net Sales:

8 Million

(Quarterly Results - Jun 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.68%

6 Months

10.69%

1 Year

-28.09%

2 Years

-24.42%

3 Years

-54.96%

4 Years

-83.27%

5 Years

-85.15%

Enzymatica AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-10.37%

EBIT Growth (5y)

-187.97%

EBIT to Interest (avg)

-30.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.41

Sales to Capital Employed (avg)

0.39

Tax Ratio

0.15%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.61

EV to EBIT

-8.89

EV to EBITDA

-8.89

EV to Capital Employed

4.76

EV to Sales

9.46

PEG Ratio

Dividend Yield

ROCE (Latest)

-53.50%

ROE (Latest)

-36.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -32.52% vs -28.49% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 19.44% vs -35.34% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.30",
          "val2": "12.30",
          "chgp": "-32.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.90",
          "val2": "-18.30",
          "chgp": "18.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.60",
          "chgp": "-83.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.50",
          "val2": "-18.00",
          "chgp": "19.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,793.60%",
          "val2": "-1,487.20%",
          "chgp": "-30.64%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.41% vs 4.09% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.04% vs 27.66% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "45.60",
          "val2": "50.90",
          "chgp": "-10.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-46.90",
          "val2": "-44.70",
          "chgp": "-4.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "2.10",
          "chgp": "-19.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-53.20",
          "val2": "-49.70",
          "chgp": "-7.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,157.70%",
          "val2": "-1,006.40%",
          "chgp": "-15.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

8.30

12.30

-32.52%

Operating Profit (PBDIT) excl Other Income

-14.90

-18.30

18.58%

Interest

0.10

0.60

-83.33%

Exceptional Items

0.00

Consolidate Net Profit

-14.50

-18.00

19.44%

Operating Profit Margin (Excl OI)

-1,793.60%

-1,487.20%

-30.64%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -32.52% vs -28.49% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 19.44% vs -35.34% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

45.60

50.90

-10.41%

Operating Profit (PBDIT) excl Other Income

-46.90

-44.70

-4.92%

Interest

1.70

2.10

-19.05%

Exceptional Items

0.00

Consolidate Net Profit

-53.20

-49.70

-7.04%

Operating Profit Margin (Excl OI)

-1,157.70%

-1,006.40%

-15.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -10.41% vs 4.09% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -7.04% vs 27.66% in Dec 2023

All Annual Results

Company CV

About Enzymatica AB

Enzymatica AB

Pharmaceuticals & Biotechnology

Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

Company Coordinates

Company Details

Ideon Science Park, Scheelevagen 19 , LUND None : 223 70

Tel: 46 46 2863100

http://www.enzymatica.se

Registrar Details